NCT00338247Approved For Marketing不适用
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects With ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 发起方
- Novartis
- 试验地点
- 1
研究概览
简要总结
This study will provide pre-approval drug access to lapatinib, in combination with capecitabine, to patients whose breast cancer had progressed on other therapies
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (1)
Loading locations...
相似试验
Approved For Marketing
不适用
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT01931306Boehringer Ingelheim
进行中（未招募）
不适用
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer - Expanded Access study of Lapatinib and Capecitabine in ErbB2 Positive Breast CancerErbB2 Overexpressing Locally Advanced or Metastatic Breast CancerEUCTR2006-002080-93-ATGlaxo SmithKline Research and Development Limited4,000
进行中（未招募）
1 期
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer - Expanded Access study of Lapatinib and Capecitabine in ErbB2 Positive Breast CancerErbB2 Overexpressing Locally Advanced or Metastatic Breast CancerMedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-002080-93-SEGlaxo SmithKline Research and Development Limited4,000
进行中（未招募）
1 期
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer - Expanded Access study of Lapatinib and Capecitabine in ErbB2 Positive Breast CancerEUCTR2006-002080-93-CZGlaxo SmithKline Research and Development Limited4,000
进行中（未招募）
1 期
An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer - Expanded Access study of Lapatinib and Capecitabine in ErbB2 Positive Breast CancerEUCTR2006-002080-93-IEGlaxo SmithKline Research and Development Limited4,000